Savara- announces final clinical study design for impala 2, next phase 3 study of molgradex in autoimmune pulmonary alveolar proteinosis

Savara reports second quarter 2020 financial results and provides business update.q2 loss per share $0.16.q2 earnings per share estimate $-0.24 -- refinitiv ibes data.savara- announces final clinical study design for impala 2, next phase 3 study of molgradex in autoimmune pulmonary alveolar proteinosis.phase 3 impala 2 study is expected to start in q1 of 2021.
SVRA Ratings Summary
SVRA Quant Ranking